 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || RCT1100 / ReCode Therap
New P1 trial: Study of Inhaled RCT1100 in Adults with PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance (clinicaltrials.gov) - Oct 8, 2024
P1, N=12, Not yet recruiting, Sponsor: ReCode Therapeutics
- || RCT1100 / ReCode Therap
Enrollment open: A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults with PCD (clinicaltrials.gov) - Sep 22, 2024
P1, N=10, Recruiting, Sponsor: ReCode Therapeutics
Not yet recruiting --> Recruiting
- | RCT1100 / ReCode Therap
Enrollment closed: Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - Sep 20, 2024
P1, N=9, Active, not recruiting, Sponsor: ReCode Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || RCT1100 / ReCode Therap
New P1 trial: A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults with PCD (clinicaltrials.gov) - Sep 19, 2024
P1, N=10, Not yet recruiting, Sponsor: ReCode Therapeutics
- || RCT1100 / ReCode Therap
Enrollment change, Trial completion date, Trial primary completion date: Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - Dec 15, 2023
P1, N=9, Recruiting, Sponsor: ReCode Therapeutics
Recruiting --> Active, not recruiting N=32 --> 9 | Trial completion date: Dec 2025 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
- || RCT1100 / ReCode Therap
Enrollment open: Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - Feb 24, 2023
P1, N=32, Recruiting, Sponsor: ReCode Therapeutics
N=32 --> 9 | Trial completion date: Dec 2025 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Sep 2024 Not yet recruiting --> Recruiting
- || RCT1100 / ReCode Therap
New P1 trial: Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - Feb 21, 2023
P1, N=32, Not yet recruiting, Sponsor: ReCode Therapeutics